Precision Drilling Corporation ( PDS ) Nowojorska Giełda Papierów Wartościowych

Cena: 47.02 ( 1.97% )

Aktualizacja 06-26 21:59
Nowojorska Giełda Papierów Wartościowych
Branża: Oil & Gas Drilling
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Energetyka
Branża: Oil & Gas Drilling
Zatrudnienie: 5 000
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 96%
Ilość akcji: 14 336 500
Debiut giełdowy: 1996-11-15
WWW: https://www.precisiondrilling.com
CEO: Mr. Kevin A. Neveu B.Sc., P.Eng
Adres: 525–8th Avenue SW
Siedziba: T2P 1G1 Calgary
ISIN: CA74022D4075
Opis firmy:

Precision Drilling Corporation, firma wiertnicza, zapewnia usługi wiercenia, ukończenia i produkcji dla firm zajmujących się poszukiwaniem i produkcją w branży naftowej i ziemnej i geotermalnej w Ameryce Północnej i na Bliskim Wschodzie. Firma działa w dwóch segmentach, usług wiercenia umów; oraz usługi ukończenia i produkcji. Segment usług wiercenia kontraktowego oferuje usługi wiercenia studni na lądzie dla firm eksploracyjnych i produkcyjnych w przemyśle naftowym i gazowym. Usługi tego segmentu obejmują wiertło gruntów i pod klucz; oraz zamówienia i dystrybucja materiałów naftowych, a także produkcja i renowacja sprzętu wiertniczego i serwisowego. Na dzień 31 grudnia 2021 r. Obsługiwał 227 platform wiertniczych, w tym 109 w Kanadzie; 105 w Stanach Zjednoczonych; 6 w Kuwejcie; 4 w Arabii Saudyjskiej; 2 w regionie Kurdystanu w Iraku; i 1 w kraju Gruzji. Na dzień 31 grudnia 2021 r. Segment ten obsługiwał również 47 platform alphatm z alfaautomacją komercyjną; 18 alfaapps; 4 platformy zdolne do zasilania siatki; oraz 60 zestawów gazu ziemnego lub bi-paliw. Segment usług ukończenia i produkcji zapewnia platformy serwisowe w celu ukończenia, pracy, porzucenia, konserwacji i ponownego wejścia na rzecz przygotowania; Zakwaterowanie wellsite; Wypożyczalnia wyposażenia powierzchniowego naftowego; oraz usługi obozowe i gastronomiczne dla firm zajmujących się poszukiwaniem ropy i gazu ziemnego. Na dzień 31 grudnia 2021 r. Obsługiwał 123 platformy do ukończenia studni i obsługi, w tym 113 w Kanadzie i 10 w Stanach Zjednoczonych; 1 900 pozycji wynajmu pola naftowego, w tym magazynowanie powierzchni, oczyszczanie ścieków małego przepływu, wytwarzanie energii i urządzenia sterujące ciałami stałymi; 109 jednostek zakwaterowania wellsite; 943 Łóżka obozowe; 822 bazowe łóżka obozowe; i trzech restauracji w Kanadzie. Precision Drilling Corporation został zarejestrowany w 1951 roku i ma siedzibę w Calgary w Kanadzie.

Wskaźniki finansowe
Kapitalizacja (USD) 641 583 198
Aktywa: 2 887 996 000
Cena: 47.02
Wskaźnik Altman Z-Score: 1.0
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: 8.6
Ilość akcji w obrocie: 96%
Średni wolumen: 138 616
Ilość akcji 13 644 900
Wskaźniki finansowe
Przychody TTM 1 941 028 000
Zobowiązania: 1 226 896 000
Przedział 52 tyg.: 36.2 - 79.07
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: 5.4
P/E branży: 6.7
Beta: 2.748
Raport okresowy: 2025-07-28
WWW: https://www.precisiondrilling.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Gene C. Stahl President of North American Drilling 877 181 1974
Mr. Carey Thomas Ford C.F.A. Chief Financial Officer 864 183 0
Mr. Shuja U. Goraya Chief Technology Officer 790 176 0
Ms. Veronica H. Foley Chief Legal & Compliance Officer 787 162 0
Mr. Grant Hunter Senior Vice President of North American Drilling Operation 526 867 0
Mr. Darren J. Ruhr Chief Administrative Officer 414 275 0
Mr. Kevin A. Neveu B.Sc., P.Eng President, Chief Executive Officer & Director 1 956 124 1961
Mr. Ross Steven Pickering Senior Vice President of Global Operations Excellence 0 1946
Dustin Honing Manager of Investor Relations & Corporate Development 0 0
Ms. Lavonne Zdunich Director of Investor Relations 0 0
Wiadomości dla Precision Drilling Corporation
Tytuł Treść Źródło Aktualizacja Link
Precision Drilling Corporation Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders CALGARY, Alberta, May 15, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) is pleased to announce the results of the election of board members at its 2025 Annual and Special Meeting of Shareholders held on May 15, 2025 (the Annual Meeting). Shareholders approved the election of all eight (seven of whom are independent) of the nominee directors presented in the Company's Management Information Circular (the Circular), dated April 2, 2025. globenewswire.com 2025-05-15 21:00:00 Czytaj oryginał (ang.)
EMV Capital portfolio company PDS Biotech advances cancer trial PDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head and neck cancers linked to HPV16. The trial, which will enrol around 350 patients, is supported by the US Food and Drug Administration Fast Track designation and includes interim data readouts. proactiveinvestors.co.uk 2025-05-15 06:53:50 Czytaj oryginał (ang.)
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J. globenewswire.com 2025-05-14 11:30:00 Czytaj oryginał (ang.)
PDS Health Expands CyberArk Deployment to Automate Certificate Lifecycle Management at Scale NEWTON, Mass. & PETACH TIKVA, Israel--(BUSINESS WIRE)--CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that PDS Health, a leading integrated healthcare support organization serving more than 1,000 dental and primary care practices across the U.S., will extend its CyberArk implementation with additional machine identity security solutions. By adding CyberArk Zero Touch PKI and CyberArk Certificate Manager to its identity security program, PDS Health will moderniz. businesswire.com 2025-05-13 11:30:00 Czytaj oryginał (ang.)
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on May 5, 2025, PDS Biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech. globenewswire.com 2025-05-09 20:05:00 Czytaj oryginał (ang.)
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m. globenewswire.com 2025-05-07 12:00:00 Czytaj oryginał (ang.)
Precision Drilling Corporation (PDS) Q1 2025 Earnings Call Transcript Precision Drilling Corporation (NYSE:PDS ) Q1 2025 Earnings Conference Call April 24, 2025 1:00 PM ET Company Participants Lavonne Zdunich - Vice President of Investor Relations Carey Ford - Chief Financial Officer Kevin Neveu - President, Chief Executive Officer & Director Conference Call Participants Aaron MacNeil - TD Cowen Keith MacKey - RBC Capital Markets Waqar Syed - ATB Capital Markets John Gibson - BMO Capital Markets John Daniel - Daniel Energy Partners Aaron Rosenthal - JPMorgan Operator Good day and thank you for standing by. Welcome to the Precision Drilling Corporation 2025 First Quarter Results Conference Call and Webcast. seekingalpha.com 2025-04-25 01:25:07 Czytaj oryginał (ang.)
Precision Drilling (PDS) Misses Q1 Earnings and Revenue Estimates Precision Drilling (PDS) came out with quarterly earnings of $1.53 per share, missing the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.88 per share a year ago. zacks.com 2025-04-23 23:45:28 Czytaj oryginał (ang.)
Precision Drilling Announces 2025 First Quarter Unaudited Financial Results CALGARY, Alberta, April 23, 2025 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, gain on investments and other assets, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Funds Provided by (Used in) Operations, Net Capital Spending, Working Capital and Total Long-term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards ( IFRS ) Accounting Standards and may not be comparable to similar measures used by other companies. See “Financial Measures and Ratios” later in this news release. globenewswire.com 2025-04-23 21:30:00 Czytaj oryginał (ang.)
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that three abstracts on Versamune® HPV (PDS0101) have been accepted for presentation at the 2025 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 30-June 3, 2025, in Chicago, Illinois. globenewswire.com 2025-04-23 14:16:00 Czytaj oryginał (ang.)
Earnings Preview: Precision Drilling (PDS) Q1 Earnings Expected to Decline Precision Drilling (PDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-16 15:06:37 Czytaj oryginał (ang.)
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel Infectimune® based flu vaccine will be featured in a symposium on universal influenza vaccines at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, taking place May 3-7, 2025, in Honolulu, Hawaii. globenewswire.com 2025-04-16 12:00:00 Czytaj oryginał (ang.)
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that an abstract submitted by the National Cancer Institute (“NCI”) reporting clinical data on PDS01ADC, the Company's IL-12 fused antibody drug conjugate, has been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. globenewswire.com 2025-04-08 12:00:00 Czytaj oryginał (ang.)
Precision Drilling Corporation Announces Filing of Management Information Circular and Virtual-Only Annual and Special Meeting of Shareholders CALGARY, Alberta, April 02, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) (TSX:PD; NYSE:PDS) announces today the filing of its Management Information Circular (the Circular) issued in connection with the 2025 Annual and Special Meeting of Shareholders (the Annual Meeting). A copy of the Circular can be downloaded from the Company's SEDAR+ profile at www.sedarplus.ca and the Company's EDGAR profile at www.sec.gov. The Circular is also available on Precision's website at www.precisiondrilling.com. globenewswire.com 2025-04-02 20:15:00 Czytaj oryginał (ang.)
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ® HPV in HPV16-Positive Head and Neck Cancer globenewswire.com 2025-03-27 09:30:00 Czytaj oryginał (ang.)
Precision Drilling Corporation 2025 First Quarter Results Conference Call and Webcast CALGARY, Alberta, March 26, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2025 first quarter results after the market closes on Wednesday, April 23, 2025, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Thursday, April 24, 2025. globenewswire.com 2025-03-26 18:00:00 Czytaj oryginał (ang.)
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025. globenewswire.com 2025-03-25 10:00:00 Czytaj oryginał (ang.)
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m. globenewswire.com 2025-03-18 10:00:00 Czytaj oryginał (ang.)
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the Versamune ® platform and various immunocytokines, including PDS01ADC recently issued PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (“IND”) application filed in January 2025 to evaluate a combination of Versamune® MUC1 (formerly PDS0103), its novel investigational MUC1-targeted immunotherapy candidate + PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma (“mCRC”) in patients who failed previous treatment. globenewswire.com 2025-03-13 10:00:00 Czytaj oryginał (ang.)
PDS Biotech Leadership to Participate in March Conferences PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025. globenewswire.com 2025-03-11 10:00:00 Czytaj oryginał (ang.)
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation from certain directors of the Company, for the purchase and sale of 7,330,121 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering") at a combined purchase price of $1.50 for the institutional investors and $1.66 for certain directors of the Company. globenewswire.com 2025-02-27 10:00:00 Czytaj oryginał (ang.)
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant tumor shrinkage with confirmed objective response rate (ORR) of 75% in HPV16-positive immune checkpoint inhibitor naïve patients; Historically published result is 11-24% PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of clinical results in the Journal of the American Medical Association (JAMA) Oncology. globenewswire.com 2025-02-26 10:00:00 Czytaj oryginał (ang.)
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 globenewswire.com 2025-02-24 10:00:00 Czytaj oryginał (ang.)
Precision Drilling: Accelerating Capital Returns Should Put A Floor On The Stock Precision Drilling Corporation underwhelmed in its Q4-2024 report. The company did deliver on its debt reduction target and cash flow should start flowing increasingly in the direction of shareholders. We go over the numbers and tell you how we are playing this. seekingalpha.com 2025-02-20 21:17:56 Czytaj oryginał (ang.)
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B. globenewswire.com 2025-02-20 10:00:00 Czytaj oryginał (ang.)
Precision Drilling Corporation (PDS) Q4 2024 Earnings Call Transcript Precision Drilling Corporation (NYSE:PDS ) Q4 2024 Earnings Conference Call February 13, 2025 1:00 PM ET Company Participants Lavonne Zdunich - VP, Investor Relations Carey Ford - CFO Kevin Neveu - President, CEO & Director Conference Call Participants Aaron MacNeil - TD Cowen Kurt Hallead - Benchmark Sean Mitchell - Daniel Energy Partners Keith MacKey - RBC Capital Markets Waqar Syed - ATB Capital Markets Operator Good day, and thank you for standing by. Welcome to the Precision Drilling Corporation 2024 Fourth Quarter and End of Year Results Conference Call and Webcast. seekingalpha.com 2025-02-13 19:49:02 Czytaj oryginał (ang.)
Precision Drilling (PDS) Misses Q4 Earnings and Revenue Estimates Precision Drilling (PDS) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $3.45 per share a year ago. zacks.com 2025-02-12 23:11:08 Czytaj oryginał (ang.)
Precision Drilling Announces 2024 Fourth Quarter and Year End Unaudited Financial Results CALGARY, Alberta, Feb. 12, 2025 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, gain on acquisition, loss on investments and other assets, gain on repurchase of unsecured senior notes, finance charges, foreign exchange, loss on asset decommissioning, gain on asset disposals and depreciation and amortization), Funds Provided by (Used in) Operations, Net Capital Spending, Working Capital and Total Long-term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards ( IFRS ) and may not be comparable to similar measures used by other companies. See “Financial Measures and Ratios” later in this news release. globenewswire.com 2025-02-12 20:45:00 Czytaj oryginał (ang.)
Precision Drilling Corporation 2024 Fourth Quarter and Year-End Results Conference Call and Webcast CALGARY, Alberta, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2024 fourth quarter and year-end results after the market closes on Wednesday, February 12, 2025 and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Thursday, February 13, 2025. globenewswire.com 2025-01-14 18:00:00 Czytaj oryginał (ang.)
Precision Drilling Meets 2024 Debt Repayment and Share Repurchase Targets and Provides Capital Allocation, Financial and Operational Updates This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release. globenewswire.com 2025-01-07 08:00:00 Czytaj oryginał (ang.)
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech. globenewswire.com 2024-12-06 10:00:00 Czytaj oryginał (ang.)
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation globenewswire.com 2024-12-03 10:00:00 Czytaj oryginał (ang.)
Drill Bit Market Size Will Hit USD 4.12 Billion by 2032, Owing to Increasing Demand for Precision Drilling Technologies | Report by SNS Insider “The global drill bit market is expanding rapidly, driven by rising demand from industries like oil & gas, mining, aerospace, and construction for durable, high-performance drilling technologies.” “The global drill bit market is expanding rapidly, driven by rising demand from industries like oil & gas, mining, aerospace, and construction for durable, high-performance drilling technologies.” globenewswire.com 2024-11-19 13:52:00 Czytaj oryginał (ang.)
Precision Drilling: Capitalizing On Strong Activity In Canada Precision Drilling's Q3 report shows strong performance in Canada, where rig demand is at multiyear highs. While the U.S. market remains a weakness, Precision Drilling is generating adequate margins on its super spec rigs that remain in tight supply. When U.S. activity rebounds, Precision Drilling will benefit from the much higher pricing that will be necessary to balance the market. seekingalpha.com 2024-11-18 01:59:20 Czytaj oryginał (ang.)
EMV Capital highlights progress update from portfolio company PDS Biotech EMV Capital (AIM:EMVC) has noted the clinical progress update from portfolio company PDS Biotechnology alongside its third-quarter update. Frank Bedu-Addo, PDS chief executive, said:  "Since our last update in August, we have been actively engaged with investors and clinicians to discuss our strategy and funding requirements for our VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab compared to pembrolizumab as a potential treatment for first-line recurrent/metastatic HPV16-positive head and neck squamous cell cancer (HNSCC). proactiveinvestors.co.uk 2024-11-14 13:03:31 Czytaj oryginał (ang.)
Patterson Dental Extends Strategic Relationship With PDS Health ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Dental Supply, Inc., a subsidiary of Patterson Companies, Inc. (Nasdaq: PDCO), today announced an agreement in principle between Patterson and PDS Health, a leading dental and medical support organization formerly known as Pacific Dental Services, to extend their strategic relationship through the end of 2027. The extension allows Patterson to continue as the premier distributor for all merchandise, services, technology and core equipment across PDS H. businesswire.com 2024-11-13 09:00:00 Czytaj oryginał (ang.)
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a.m. Eastern Time. globenewswire.com 2024-11-06 10:00:00 Czytaj oryginał (ang.)
Precision Drilling Corporation (PDS) Q3 2024 Earnings Conference Call Transcript Precision Drilling Corporation (NYSE:PDS ) Q3 2024 Earnings Conference Call October 30, 2024 1:00 PM ET Company Participants Lavonne Zdunich - VP, IR Carey Ford - CFO Kevin Neveu - President and CEO Conference Call Participants Kurt Hallead - Benchmark Waqar Syed - ATB Capital Markets Sean Mitchell - Daniel Energy Partners John Gibson - BMO Capital Markets Keith Mackey - RBC Capital Markets Aaron MacNeil - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Precision Drilling Corporation 2024 Third Quarter Conference Call. seekingalpha.com 2024-10-30 19:16:02 Czytaj oryginał (ang.)
Precision Drilling (PDS) Surpasses Q3 Earnings Estimates Precision Drilling (PDS) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.55 per share. This compares to earnings of $1.08 per share a year ago. zacks.com 2024-10-29 21:41:14 Czytaj oryginał (ang.)
Precision Drilling Announces 2024 Third Quarter Unaudited Financial Results CALGARY, Alberta, Oct. 29, 2024 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, loss (gain) on investments and other assets, gain on repurchase of unsecured senior notes, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Funds Provided by (Used in) Operations, Net Capital Spending, Working Capital and Total Long-term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards ( IFRS ) Accounting Standards and may not be comparable to similar measures used by other companies. See “Financial Measures and Ratios” later in this news release. globenewswire.com 2024-10-29 19:25:00 Czytaj oryginał (ang.)
Precision Drilling Corporation 2024 Third Quarter Results Conference Call and Webcast CALGARY, Alberta, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2024 third quarter results after the market closes on Tuesday, October 29, 2024, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, October 30, 2024. globenewswire.com 2024-10-02 20:00:00 Czytaj oryginał (ang.)
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully  treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024 globenewswire.com 2024-10-02 12:00:00 Czytaj oryginał (ang.)
Precision Drilling: Get 20% Free Cash Flow Yield At The Cyclical Bottom U.S. drilling activity is at a cyclical bottom, but Canada is at multiyear highs. The Canadian exposure and its high-spec rigs allow Precision Drilling to maintain a 20% FCF yield even now. Investors can benefit from Precision Drilling's buybacks while waiting for the turnaround in the U.S. seekingalpha.com 2024-09-24 03:07:32 Czytaj oryginał (ang.)
PDS Biotechnology: Continuing The Holding Pattern PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipeline, while risks involve typical biotech uncertainties and financial sustainability. The bottom-line summary suggests a cautious yet optimistic outlook, emphasizing the importance of upcoming clinical milestones and financial health. seekingalpha.com 2024-09-23 14:39:38 Czytaj oryginał (ang.)
Precision Drilling Announces Renewal of Normal Course Issuer Bid CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release. globenewswire.com 2024-09-13 10:00:00 Czytaj oryginał (ang.)
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024 PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) during a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain. globenewswire.com 2024-09-09 12:00:00 Czytaj oryginał (ang.)
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. globenewswire.com 2024-09-03 12:00:00 Czytaj oryginał (ang.)
5 Stocks With Low Price-to-Sales Ratios to Elevate Your Portfolio The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like BTU, PSMT, HG, PDS and GBX hold promise. zacks.com 2024-08-28 12:45:36 Czytaj oryginał (ang.)
Is Precision Drilling (PDS) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-08-27 14:42:01 Czytaj oryginał (ang.)
Despite Fast-paced Momentum, Precision Drilling (PDS) Is Still a Bargain Stock If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Precision Drilling (PDS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com 2024-08-27 13:50:46 Czytaj oryginał (ang.)